Literature DB >> 20736993

Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia.

Byron K Y Bitanihirwe1, Daria Peleg-Raibstein, Forouhar Mouttet, Joram Feldon, Urs Meyer.   

Abstract

Based on the human epidemiological association between prenatal infection and higher risk of schizophrenia, a number of animal models have been established to explore the long-term brain and behavioral consequences of prenatal immune challenge. Accumulating evidence suggests that the vulnerability to specific forms of schizophrenia-related abnormalities is critically influenced by the precise timing of the prenatal immunological insult. In the present study, we tested the hypothesis whether late prenatal immune challenge in mice may induce long-term behavioral and neurochemical dysfunctions primarily associated with the negative symptoms of schizophrenia. We found that prenatal exposure to the viral mimic polyriboinosinic-polyribocytidilic acid (Poly-I:C; 5 mg/kg, i.v.) on gestation day (GD) 17 led to significant deficits in social interaction, anhedonic behavior, and alterations in the locomotor and stereotyped behavioral responses to acute apomorphine (APO) treatment in both male and female offspring. In addition, male but not female offspring born to immune challenged mothers displayed behavioral/cognitive inflexibility as indexed by the presence of an abnormally enhanced latent inhibition (LI) effect. Prenatal immune activation in late gestation also led to numerous, partly sex-specific changes in basal neurotransmitter levels, including reduced dopamine (DA) and glutamate contents in the prefrontal cortex and hippocampus, as well as reduced γ-aminobutyric acid (GABA) and glycine contents in the hippocampus and prefrontal cortex, respectively. The constellation of behavioral and neurochemical abnormalities emerging after late prenatal Poly-I:C exposure in mice leads us to conclude that this immune-based experimental model provides a powerful neurodevelopmental animal model especially for (but not limited to) the negative symptoms of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20736993      PMCID: PMC3055332          DOI: 10.1038/npp.2010.129

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  92 in total

Review 1.  The structure of negative symptoms within schizophrenia: implications for assessment.

Authors:  Jack J Blanchard; Alex S Cohen
Journal:  Schizophr Bull       Date:  2005-10-27       Impact factor: 9.306

2.  Positive and negative schizophrenic symptoms and the role of dopamine.

Authors:  T J Crow
Journal:  Br J Psychiatry       Date:  1980-10       Impact factor: 9.319

Review 3.  Perseveration in schizophrenia.

Authors:  A Crider
Journal:  Schizophr Bull       Date:  1997       Impact factor: 9.306

Review 4.  The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.

Authors:  Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2003-02-25       Impact factor: 4.530

Review 5.  Affective traits in schizophrenia and schizotypy.

Authors:  William P Horan; Jack J Blanchard; Lee Anna Clark; Michael F Green
Journal:  Schizophr Bull       Date:  2008-07-29       Impact factor: 9.306

6.  The relationships of anhedonia and the process-reactive dimension to season of birth and infectious disease incidence in schizophrenia.

Authors:  C G Watson; T Kucala; G Angulski; P Vassar
Journal:  J Nerv Ment Dis       Date:  1987-01       Impact factor: 2.254

7.  Comparison of acute phase responses induced in rabbits by lipopolysaccharide and double-stranded RNA.

Authors:  M Kimura; L A Toth; H Agostini; A B Cady; J A Majde; J M Krueger
Journal:  Am J Physiol       Date:  1994-12

Review 8.  In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice.

Authors:  J F Cryan; C Mombereau
Journal:  Mol Psychiatry       Date:  2004-04       Impact factor: 15.992

Review 9.  Negative symptoms in schizophrenia: avolition and Occam's razor.

Authors:  George Foussias; Gary Remington
Journal:  Schizophr Bull       Date:  2008-07-21       Impact factor: 9.306

10.  Neural basis of psychosis-related behaviour in the infection model of schizophrenia.

Authors:  Urs Meyer; Joram Feldon
Journal:  Behav Brain Res       Date:  2008-12-30       Impact factor: 3.332

View more
  85 in total

1.  The viral theory of schizophrenia revisited: abnormal placental gene expression and structural changes with lack of evidence for H1N1 viral presence in placentae of infected mice or brains of exposed offspring.

Authors:  S Hossein Fatemi; Timothy D Folsom; Robert J Rooney; Susumu Mori; Tess E Kornfield; Teri J Reutiman; Rachel E Kneeland; Stephanie B Liesch; Kegang Hua; John Hsu; Divyen H Patel
Journal:  Neuropharmacology       Date:  2011-01-26       Impact factor: 5.250

Review 2.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

Review 3.  Inflammation and the two-hit hypothesis of schizophrenia.

Authors:  Keith A Feigenson; Alex W Kusnecov; Steven M Silverstein
Journal:  Neurosci Biobehav Rev       Date:  2013-11-15       Impact factor: 8.989

4.  Strain-specific vulnerability to alcohol exposure in utero via hippocampal parent-of-origin expression of deiodinase-III.

Authors:  Laura J Sittig; Pradeep K Shukla; Laura B K Herzing; Eva E Redei
Journal:  FASEB J       Date:  2011-03-23       Impact factor: 5.191

5.  Maternal immune activation produces cerebellar hyperplasia and alterations in motor and social behaviors in male and female mice.

Authors:  Tooka Aavani; Shadna A Rana; Richard Hawkes; Quentin J Pittman
Journal:  Cerebellum       Date:  2015-10       Impact factor: 3.847

Review 6.  The "quad-partite" synapse: microglia-synapse interactions in the developing and mature CNS.

Authors:  Dorothy P Schafer; Emily K Lehrman; Beth Stevens
Journal:  Glia       Date:  2012-07-24       Impact factor: 7.452

7.  Prenatal immune challenge in rats: altered responses to dopaminergic and glutamatergic agents, prepulse inhibition of acoustic startle, and reduced route-based learning as a function of maternal body weight gain after prenatal exposure to poly IC.

Authors:  Charles V Vorhees; Devon L Graham; Amanda A Braun; Tori L Schaefer; Matthew R Skelton; Neil M Richtand; Michael T Williams
Journal:  Synapse       Date:  2012-05-15       Impact factor: 2.562

8.  Activation of the maternal immune system during pregnancy alters behavioral development of rhesus monkey offspring.

Authors:  Melissa D Bauman; Ana-Maria Iosif; Stephen E P Smith; Catherine Bregere; David G Amaral; Paul H Patterson
Journal:  Biol Psychiatry       Date:  2013-09-05       Impact factor: 13.382

9.  Prenatal immune activation induces maturation-dependent alterations in the prefrontal GABAergic transcriptome.

Authors:  Juliet Richetto; Francesca Calabrese; Marco A Riva; Urs Meyer
Journal:  Schizophr Bull       Date:  2013-01-17       Impact factor: 9.306

10.  Oligodendroglial alterations and the role of microglia in white matter injury: relevance to schizophrenia.

Authors:  Li-Jin Chew; Paolo Fusar-Poli; Thomas Schmitz
Journal:  Dev Neurosci       Date:  2013-02-27       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.